XML 60 R48.htm IDEA: XBRL DOCUMENT
v3.21.1

Commitments and Contingencies - Additional Information (Detail) - AGC Biologics, Inc - Marzeptacog Alfa Activated and Dalcinonacog Alfa $ in Millions | Mar. 31, 2021 USD ($)
--- | ---
Commitments And Contingencies Disclosure [Line Items] |
Firm work order supporting clinical trials | $ 17.1
Contractual obligation payments | $ 4.5

X
- Definition Commitments and contingencies disclosure. + References No definition available. + Details
Name: | cbio_CommitmentsAndContingenciesDisclosureLineItems
Namespace Prefix: | cbio_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Firm work order supporting clinical trials. + References No definition available. + Details
Name: | cbio_FirmWorkOrderSupportingClinicalTrials
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments. + References No definition available. + Details
Name: | us-gaap_ContractualObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | srt_CounterpartyNameAxis=cbio_AGCBiologicsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |